N6-methyladenosine (m6A) RNA modification restrains antifungal immunity and is a therapeutic target in oral candidiasis

m6A RNA modification acts as a bidirectional regulator of oral epithelial immune responses to Candida albicans, influencing disease severity and potential therapy.

• Why it matters: Understanding posttranscriptional regulation of immune genes is crucial because fungal infections like oral candidiasis lack vaccines and pose a global health threat, especially in immunocompromised individuals.
• What they did: The study examined the role of m6A RNA modifications by blocking core machinery components, including methylases and binding proteins, and observed effects on host defense transcripts and immune responses in murine models.
• The result: Inhibiting METTL3 increased cytokine expression, reduced fungal burden, and alleviated disease, highlighting the m6A pathway as a promising target for therapeutic intervention in mucosal candidiasis.